Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2016
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X
Form
40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __ No
X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule
12g3-2(b): 82-_____________
22 September 2016 11.00
New
external board appointment
Listing
Rule LR 9.6.14 R (2)
Ann
Cairns, a Non-Executive Director of AstraZeneca PLC, is expected to
join the Board of Directors of Intercontinental Exchange, Inc., a
company listed on the New York Stock Exchange, effective from
2017.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Respiratory and Autoimmunity, Cardiovascular
and Metabolic Diseases, and
Oncology. The Company is also active in inflammation, infection and
neuroscience through numerous collaborations. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please
visit: www.astrazeneca.com
CONTACTS
|
Media Enquiries
|
|
|
|
Neil
Burrows
|
UK/Global
|
+44
203 749 5637
|
|
Vanessa
Rhodes
|
UK/Global
|
+44
203 749 5736
|
|
Karen
Birmingham
|
UK/Global
|
+44
203 749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44
203 749 5821
|
|
Jacob
Lund
|
Sweden
|
+46
8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
Investor Relations
|
|
|
|
UK
|
|
|
|
Thomas Kudsk Larsen
|
|
+44 203 749 5712
|
|
Craig Marks
|
Finance, Fixed Income, M&A
|
+44 7881 615 764
|
|
Nick Stone
|
Respiratory & Autoimmunity
|
+44 203 749 5716
|
|
Henry Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Christer Gruvris
|
Infection & Neuroscience
|
+44 203 749 5711
|
|
US
|
|
|
|
Lindsey Trickett
|
Cardiovascular & Metabolic Diseases
|
+1 240
543 7970
|
|
Mitchell Chan
|
Oncology
|
+1 240
477 3771
|
|
Toll-free
|
|
+1 866
381 7277
|
Adrian
Kemp
Company
Secretary
AstraZeneca
PLC
-ENDS-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
AstraZeneca
PLC
Date:
22 September
2016
By: /s/
Adrian Kemp
Name:
Adrian Kemp
Title:
Company Secretary